Claims
- 1. A compound having the structural formula (I)
- 2. The compound of claim 1, wherein R is C1-C24 hydrocarbyl.
- 3. The compound of claim 2, wherein R is selected from the group consisting of carbyl, alkylene, alkenylene, alkynylene and arylene, if alkylene, alkenylene, alkynylene, arylene or aralkylene, optionally substituted with 1 to 6 substituents selected from the group consisting of—L—R1, lower alkyl, amino, lower alkyl-substituted amino, nitro, halo, halogenated lower alkyl, halogenated amino, and —NR7(NO2), wherein R7 is hydrogen or lower hydrocarbyl.
- 4. The compound of claim 3, wherein R is selected from the group consisting of carbyl, lower alkylene and lower alkenylene.
- 5. The compound of claim 1, wherein R is —L—R1 and n is 1.
- 6. The compound of claim 1, wherein L is lower alkylene.
- 7. The compound of claim 5, wherein R is lower alkylene.
- 8. The compound of claim 1, wherein R1 is —ONR2R3 or —ONR2R3+Y−.
- 9. The compound of claim 5, wherein R1 is —ONR2R3 or —ONR2R3+Y−.
- 10. The compound of claim 1, wherein R1 has the structure
- 11. The compound of claim 1, wherein R1 is —ON═CR5R6 or —O—[N═CR5R6]H+Y−.
- 12. The compound of claim 5, wherein R1 is —ON═CR5R6 or —O—[N═CR5R6]H+Y−.
- 13. A compound having the structural formula (I)
- 14. The compound of claim 13, wherein R is —L—R1 and n is 1.
- 15. The compound of claim 14, wherein R has the structure
- 16. The compound of claim 14, wherein R has the structure
- 17. The compound of claim 14, wherein R has the structure
- 18. A compound having the structural formula (I)
- 19. The compound of claim 18, wherein R is selected from the group consisting of polyolefins, halogenated vinyl polymers, cellulosic polymers, nitrogenous polymers and polyglycols.
- 20. The compound of claim 19, wherein R is a polyolefin.
- 21. The compound of claim 20, wherein R is selected from the group consisting of polyethylene, polypropylene and polyisoprene.
- 22. The compound of claim 19, wherein R is a halogenated vinyl polymer.
- 23. The compound of claim 22, wherein R is selected from the group consisting of polytrifluoroethylene, poly(vinyl fluoride) and poly(vinylidene chloride).
- 24. The compound of claim 19, wherein R is a polyglycol.
- 25. The compound of claim 24, wherein R is polyoxymethylene or poly(ethylene oxide).
- 26. The compound of claim 1, having the structural formula
- 27. The compound of claim 1, having the structural formula
- 28. The compound of claim 1, having the structural formula
- 29. The compound of claim 1, having the structural formula
- 30. The compound of claim 1, having the structural formula
- 31. The compound of claim 1, having the structural formula
- 32. A gas-generating composition comprising an igniter and a secondary explosive that comprises the compound of claim 1.
- 33. A gas-generating composition comprising an igniter and a secondary explosive that comprises the compound of claim 13.
- 34. A gas-generating composition comprising an igniter and a secondary explosive that comprises the compound of claim 18.
- 35. A propellant composition comprising an igniter, a binder, fuel, and a secondary explosive that comprises the compound of claim 1.
- 36. A propellant composition comprising an igniter, a binder, fuel, and a secondary explosive that comprises the compound of claim 13.
- 37. A propellant composition comprising an igniter, a binder, fuel, and a secondary explosive that comprises the compound of claim 18.
- 38. A pharmaceutical composition comprising a therapeutically effective amount of the compound of any one of claims 1, 13 and 18 in combination with a pharmaceutically acceptable carrier.
- 39. The pharmaceutical composition of claim 38, in the form of a solid.
- 40. The pharmaceutical composition of claim 39, in unit dosage form.
- 41. A method for treating a patient suffering from a condition or disorder that can be alleviated with a nitrovasodilator, comprising administering to the patient a pharmaceutical composition that comprises the compound of any one of claims 1, 13 and 18 and a pharmaceutically acceptable carrier, wherein the composition is administered in an amount effective to alleviate or treat the condition or disorder.
- 42. A method for administering a therapeutic agent to a human or animal so that the agent permeates the blood-brain barrier, comprising administering the therapeutic agent in combination with the compound of any one of claims 1, 13 and 18.
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This is a continuation-in-part of U.S. patent application Serial No. 09/168,308, filed Oct. 7, 1998.
REFERENCE TO GOVERNMENT SUPPORT
[0002] This invention was funded in part by the United States Office of Naval Research under Contract No. N00014-95-C-0209 and in part by the United States Air Force Office of Scientific Research under Contract No. AF-F04611-96-K-0013. The United States Government has certain rights in this invention.
Divisions (1)
|
Number |
Date |
Country |
Parent |
09414977 |
Oct 1999 |
US |
Child |
09877319 |
Jun 2001 |
US |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09168308 |
Oct 1998 |
US |
Child |
09414977 |
Oct 1999 |
US |